Effects of human erythropoietine in improvement of traumatic cervical cord injury

Effects of Human Recombinant Erythropoietine on Functional Outcome of Traumatic Cervical Spine Cord Injury; A Randomized Placebo Controlled Study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014122920471N1

Enrollment

Registered

2015-04-26

Start date

2012-01-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Traumatic Cervical Cord Injury. Injury of nerves and spinal cord at neck level

Interventions

Intervention 1: recombinant erythropoietin, intravenous, 500 IU, stat and repeat that after 24 hour. Intervention 2: equal volume of normal saline, intravenous, stat and 24 hour later.

Treatment - Drugs

recombinant erythropoietin, intravenous, 500 IU, stat and repeat that after 24 hour

equal volume of normal saline, intravenous, stat and 24 hour later

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Acute cervical cord injury Less than 8 hours from injury. Exclusion criteria: Anatomic cord dissection; Penetrating cord injury; Injury beyond cervical cord; Significant concomitant injury; Contraindication for methylprednisolone; Contraindication for erythropoietin; Patient refuses the study

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Neurological examination. Timepoint: Before, 1,3,6 months after intervention. Method of measurement: examining by physician.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFahim Baghban

Shiraz University of Medical Science

baghbanf@sums.ac.ir+98 71 3624 0101

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026